[go: up one dir, main page]

PE20020472A1 - Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales - Google Patents

Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales

Info

Publication number
PE20020472A1
PE20020472A1 PE2001001024A PE2001001024A PE20020472A1 PE 20020472 A1 PE20020472 A1 PE 20020472A1 PE 2001001024 A PE2001001024 A PE 2001001024A PE 2001001024 A PE2001001024 A PE 2001001024A PE 20020472 A1 PE20020472 A1 PE 20020472A1
Authority
PE
Peru
Prior art keywords
progesterone receptor
receptor inhibitor
inhibit
attachment
tumor cells
Prior art date
Application number
PE2001001024A
Other languages
English (en)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20020472A1 publication Critical patent/PE20020472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE AL USO DE UN INHIBIDOR DEL RECEPTOR DE PROGESTERONA SELECCIONADO DE 17O-FLUORALQUILESTEROIDES DE FORMULA I DONDE R1 ES METILO, ETILO; R2 ES UN RADICAL CnFmHo DONDE n ES 2-6; m ES MAYOR QUE 1 Y m+o =2n+1; R3 ES OH LIBRE ETERIFICADO O ESTERIFICADO; R4 Y R5 SON H Y JUNTOS SON UN ENLACE ADICIONAL O UN GRUPO METILO; St ES UN SISTEMA DE ANILLO ESTEROIDE ABC DE FORMULA A ENTRE OTROS DONDE R6 ES H, ALQUILO C1-C4, HALOGENO; R7 ES H, ALQUILO C1-C4; X ES O, AGRUPAMIENTO HIDROXIIMINO; R8 ES UN RADICAL ARILO ENTRE OTROS. UN COMPUESTO PREFERIDO ES 11ß-(4-ACETILFENIL)-17ß-HIDROXI-17O-(1,1,2,2,2-PENTAFLUORETIL)-ESTRA-4,9-DIEN-3-ONA. SE REFIERE TAMBIEN AL USO DE UN INHIBIDOR DEL RECEPTOR DE PROGESTERONA PARA INHIBIR LA FIJACION DE FACTORES DE CRECIMIENTO EN CELULAS TUMORALES
PE2001001024A 2000-10-18 2001-10-16 Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales PE20020472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen

Publications (1)

Publication Number Publication Date
PE20020472A1 true PE20020472A1 (es) 2002-06-15

Family

ID=7660193

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001024A PE20020472A1 (es) 2000-10-18 2001-10-16 Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales

Country Status (10)

Country Link
US (1) US20040157811A1 (es)
AR (1) AR034562A1 (es)
DE (1) DE10051609A1 (es)
EC (1) ECSP034604A (es)
PE (1) PE20020472A1 (es)
PT (1) PT1414465E (es)
TW (1) TWI234458B (es)
UY (1) UY26975A1 (es)
YU (1) YU30003A (es)
ZA (1) ZA200303785B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
AR034562A1 (es) 2004-03-03
US20040157811A1 (en) 2004-08-12
ECSP034604A (es) 2003-06-25
YU30003A (sh) 2006-08-17
PT1414465E (pt) 2007-01-31
DE10051609A1 (de) 2002-05-02
TWI234458B (en) 2005-06-21
UY26975A1 (es) 2002-06-20
ZA200303785B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
ES2196637T3 (es) Complejo soluble de dihaluro de magnesio, preparacion y uso.
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
PE44297A1 (es) Compuestos de 3-dimetilamino-2-metilfenilimino imidazolidina con actividad como agonistas de o1l para el tratamiento de la incontinencia urinaria
PE20020472A1 (es) Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales
ES2061309T3 (es) Catalizador para preparar oxido de etileno y procedimiento para su preparacion y uso.
ES8401495A1 (es) Procedimiento para preparar nuevos derivados de 3-ceto- 4,9,19-nor-esteroides.
AR240929A2 (es) "n-piridinsulfonil-n'-piridinil-y-triazinil-ureas procedimiento parasu preparacion, intermediarios para uso exclusivo en dicho procedimiento, y composiciones que contienen dichas ureas"
ES2036580T3 (es) Composiciones quimicas y su uso como aditivos a combustibles.
TR200001706T2 (tr) Fosfodiester IV inhibisyonuna sahip purin türevleri
ES2156029T3 (es) Procedimiento para la supervision de la ejecucion prescrita de programas de software.
CO5271716A1 (es) Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
BR0007864A (pt) Composto, e, uso de um composto
ES8402279A1 (es) Procedimiento para la preparacion de nuevos benzo-heterociclos.
ES2087477T3 (es) Derivados de pirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica.
CO4870798A1 (es) Tisu que contiene compuestos de amidoamina cationica y me- todo para su elaboracion
CO5210883A1 (es) DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO [4,5,-b]INDOL- 1-ACETAMIDA
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
CO5251441A1 (es) Compuestos esteroides que contienen un anillo de ciclopropano
AU5980399A (en) Indolin derivatives as sun protection agents
CO5271679A1 (es) Inhibidores de proteasa 7-14 miembros
DK0593487T3 (da) Vandigt autoxidativt tørrende alkydpræparat
CO5160255A1 (es) DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO[4,5-b]INDOL-1- CARBOXAMIDA Y COMPOSICIONES QUE LOS COMPRENDEN
DK184085A (da) Heterocycliske aminoforbindelser
ES2142320T3 (es) Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
CO5180536A1 (es) Inhibidores de proteasas catepsina

Legal Events

Date Code Title Description
FC Refusal